Welcome to LookChem.com Sign In|Join Free
  • or
4-amino-5-phenyl-7-(β-D-ribofuranosyl)-7H-pyrrolo[2,3-d]pyrimidine is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1252857-91-2

Post Buying Request

1252857-91-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1252857-91-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1252857-91-2 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,5,2,8,5 and 7 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1252857-91:
(9*1)+(8*2)+(7*5)+(6*2)+(5*8)+(4*5)+(3*7)+(2*9)+(1*1)=172
172 % 10 = 2
So 1252857-91-2 is a valid CAS Registry Number.

1252857-91-2Downstream Products

1252857-91-2Relevant academic research and scientific papers

Revisiting tubercidin against kinetoplastid parasites: Aromatic substitutions at position 7 improve activity and reduce toxicity

Hulpia, Fabian,Campagnaro, Gustavo Daniel,Scortichini, Mirko,Van Hecke, Kristof,Maes, Louis,de Koning, Harry P.,Caljon, Guy,Van Calenbergh, Serge

, p. 689 - 705 (2019/01/24)

The nucleoside antibiotic tubercidin displays strong activity against different target organisms, but it is notoriously toxic to mammalian cells. The effects of tubercidin against T. brucei parasites inspired us to synthesize several C7 substituted analogs for in vitro evaluation in order to find suitable hit compounds. C7 Deazaadenosines substituted with electron-poor phenyl groups were found to have micromolar activity against T. brucei in vitro. Replacement of the phenyl for a pyridine ring gave compound 13, with submicromolar potency and much-attenuated cytotoxicity compared to tubercidin. The veterinary pathogen T. congolense was equally affected by 13 in vitro. Transporter studies in T. b. brucei indicated that 13 is taken up efficiently by both the P1 and P2 adenosine transporters, making the occurrence of transporter-related resistance and cross-resistance with diamidine drugs such as diminazene aceturate and pentamidine as well as with melaminophenyl arsenicals unlikely. Evaluation of the in vitro metabolic stability of analog 13 indicated that this analog was significantly metabolized in mouse microsomal fractions, precluding further in vivo evaluation in mouse models of HAT.

New small molecule inhibitors of histone methyl transferase DOT1L with a nitrile as a non-traditional replacement for heavy halogen atoms

Spurr, Sophie S.,Bayle, Elliott D.,Yu, Wenyu,Li, Fengling,Tempel, Wolfram,Vedadi, Masoud,Schapira, Matthieu,Fish, Paul V.

, p. 4518 - 4522 (2016/08/24)

A number of new nucleoside derivatives are disclosed as inhibitors of DOT1L activity. SARs established that DOT1L inhibition could be achieved through incorporation of polar groups and small heterocycles at the 5-position (5, 6, 12) or by the application of alternative nitrogenous bases (18). Based on these results, CN-SAH (19) was identified as a potent and selective inhibitor of DOT1L activity where the polar 5-nitrile group was shown by crystallography to bind in the hydrophobic pocket of DOT1L. In addition, we show that a polar nitrile group can be used as a non-traditional replacement for heavy halogen atoms.

Synthesis and significant cytostatic activity of 7-hetaryl-7- deazaadenosines

Bourderioux, Aurelie,Nau?, Petr,Perlíková, Pavla,Pohl, Radek,Pichová, Iva,Votruba, Ivan,D?ubák, Petr,Kone?ny, Petr,Hajdúch, Marián,Stray, Kirsten M.,Wang, Ting,Ray, Adrian S.,Feng, Joy Y.,Birkus, Gabriel,Cihlar, Tomas,Hocek, Michal

experimental part, p. 5498 - 5507 (2011/10/08)

A series of 7-aryl- and 7-hetaryl-7-deazaadenosines were prepared by the cross-coupling reactions of unprotected or protected 7-iodo-7-deazaadenosines with (het)arylboronic acids, stannanes, or zinc halides. Nucleosides bearing 5-membered heterocycles at

NOVEL 7-DEAZAPURINE NUCLEOSIDES FOR THERAPEUTIC USES

-

Page/Page column 60 - 61, (2010/11/05)

The invention provides compounds of formula I, wherein R1, R2 and R3 have values defined in the specification and a pharmaceutically acceptable salt thereof; or an optical isomer thereof; or a mixture of optical isomers, as well as compositions comprising

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1252857-91-2